Cancer company Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) raised $96 million through the sale of 6 million shares at $16 in an IPO underwritten by BofA Merrill Lynch, Cowen, Canaccord Genuity and BTIG.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,